Dr. Jay M. Berman, MD
OB-GYN (Obstetrics & Gynecology) (Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 49
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecology Physician primary
MI license 4301039830
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Beaumont Hospital Royal Oak Royal Oak, MI
- Harper University Hospital Detroit, MI
- Sinai-Grace Hospital Detroit, MI
Medical groups
- University Physician Group (403 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 49
- Services billed
- 71
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Southfield, MI | 47 |
| Yuvafem (estradiol) Other prescribers in Southfield, MI | 14 |
| Estradiol-Norethindrone Acetat (estradiol/norethindrone acet) | 13 |
| Estradiol (Twice Weekly) (estradiol) Other prescribers in Southfield, MI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 34 payments worth $8,322 in total to this clinician.
| Hologic Sales and Service, LLC | $6,125 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $1,004 |
| Acessa Health Inc. | $700 |
| Medtronic, Inc. | $181 |
| Lilly USA, LLC | $125 |
| Mayne Pharma Commercial LLC | $33.69 |
| Cytyc Surgical Products, LLC | $23.78 |
| Organon LLC | $23.77 |
| Consulting Fee | $6,038 |
|---|---|
| Food and Beverage | $1,847 |
| Travel and Lodging | $438 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Hologic Sales and Service, LLC Oct 13, 2025 | Consulting Fee ACESSA PROVU SYSTEM · Surgical Company’s description8551984 | $2,800 |
| Hologic Sales and Service, LLC Jul 14, 2025 | Consulting Fee ACESSA PROVU SYSTEM · Surgical Company’s description8549261 | $1,488 |
| Hologic Sales and Service, LLC Dec 29, 2025 | Consulting Fee ACESSA PROVU SYSTEM · Surgical Company’s description8130910 | $1,050 |
| Acessa Health Inc. Jan 6, 2025 | Consulting Fee ACESSA PROVU SYSTEM · Surgical Company’s description8540130 | $700 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 9, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $327 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 9, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $111 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $109,455 in research payments for these studies, mostly to the institutions running them.
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc. · Active, not recruiting · NCT04333576 - Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Sev…
AbbVie Inc. - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc. - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.